HRP20030608A2 - Use of gal3 receptor antagonists for the treatment - Google Patents
Use of gal3 receptor antagonists for the treatment Download PDFInfo
- Publication number
- HRP20030608A2 HRP20030608A2 HR20030608A HRP20030608A HRP20030608A2 HR P20030608 A2 HRP20030608 A2 HR P20030608A2 HR 20030608 A HR20030608 A HR 20030608A HR P20030608 A HRP20030608 A HR P20030608A HR P20030608 A2 HRP20030608 A2 HR P20030608A2
- Authority
- HR
- Croatia
- Prior art keywords
- straight
- branched
- alkyl
- aryl
- image
- Prior art date
Links
- 229940044551 receptor antagonist Drugs 0.000 title claims description 48
- 239000002464 receptor antagonist Substances 0.000 title claims description 48
- 102100039558 Galectin-3 Human genes 0.000 title claims description 28
- 238000011282 treatment Methods 0.000 title description 16
- 108010001517 Galectin 3 Proteins 0.000 title description 2
- 125000003118 aryl group Chemical group 0.000 claims description 1036
- 125000001072 heteroaryl group Chemical group 0.000 claims description 646
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 570
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 433
- 125000003342 alkenyl group Chemical group 0.000 claims description 418
- 125000000304 alkynyl group Chemical group 0.000 claims description 418
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 411
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 395
- 150000001875 compounds Chemical class 0.000 claims description 356
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 327
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 216
- 238000000034 method Methods 0.000 claims description 204
- 125000004432 carbon atom Chemical group C* 0.000 claims description 159
- -1 methylenedioxy group Chemical group 0.000 claims description 159
- 229910052799 carbon Inorganic materials 0.000 claims description 142
- 125000000217 alkyl group Chemical group 0.000 claims description 114
- 229910052717 sulfur Inorganic materials 0.000 claims description 97
- 150000003839 salts Chemical class 0.000 claims description 92
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 85
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 81
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 77
- 239000000203 mixture Substances 0.000 claims description 72
- 208000019901 Anxiety disease Diseases 0.000 claims description 71
- 230000036506 anxiety Effects 0.000 claims description 68
- 230000027455 binding Effects 0.000 claims description 67
- 229910052801 chlorine Inorganic materials 0.000 claims description 66
- 229910052731 fluorine Inorganic materials 0.000 claims description 65
- 102000005962 receptors Human genes 0.000 claims description 64
- 108020003175 receptors Proteins 0.000 claims description 64
- 229910052739 hydrogen Inorganic materials 0.000 claims description 62
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 58
- 229910052740 iodine Inorganic materials 0.000 claims description 52
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 48
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 48
- 229910052757 nitrogen Inorganic materials 0.000 claims description 47
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 46
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 44
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
- 229910052760 oxygen Inorganic materials 0.000 claims description 38
- 150000004292 cyclic ethers Chemical class 0.000 claims description 37
- 150000004294 cyclic thioethers Chemical class 0.000 claims description 37
- 239000003937 drug carrier Substances 0.000 claims description 36
- 101000608757 Homo sapiens Galectin-3 Proteins 0.000 claims description 35
- 102000048551 human LGALS3 Human genes 0.000 claims description 35
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 28
- 101150103804 GAL3 gene Proteins 0.000 claims description 26
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 24
- 125000005485 noradamantyl group Chemical group 0.000 claims description 24
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 21
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 19
- 150000002466 imines Chemical class 0.000 claims description 16
- 150000001336 alkenes Chemical class 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 101001042451 Homo sapiens Galectin-1 Proteins 0.000 claims description 13
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 10
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 8
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 229960003638 dopamine Drugs 0.000 claims description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims description 4
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 claims description 4
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 claims description 4
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 claims description 4
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 claims description 4
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 claims description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 4
- 108091005436 5-HT7 receptors Proteins 0.000 claims 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 2
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 claims 2
- 101000822895 Homo sapiens 5-hydroxytryptamine receptor 1A Proteins 0.000 claims 2
- 101000724725 Homo sapiens 5-hydroxytryptamine receptor 1B Proteins 0.000 claims 2
- 101000783609 Homo sapiens 5-hydroxytryptamine receptor 1E Proteins 0.000 claims 2
- 101000783617 Homo sapiens 5-hydroxytryptamine receptor 2A Proteins 0.000 claims 2
- 101000689685 Homo sapiens Alpha-1A adrenergic receptor Proteins 0.000 claims 2
- 101000689698 Homo sapiens Alpha-1B adrenergic receptor Proteins 0.000 claims 2
- 101000756842 Homo sapiens Alpha-2A adrenergic receptor Proteins 0.000 claims 2
- 101000929512 Homo sapiens Alpha-2B adrenergic receptor Proteins 0.000 claims 2
- 101000720032 Homo sapiens Alpha-2C adrenergic receptor Proteins 0.000 claims 2
- 101001042446 Homo sapiens Galectin-2 Proteins 0.000 claims 2
- 229960001340 histamine Drugs 0.000 claims 2
- 108091005482 5-HT4 receptors Proteins 0.000 claims 1
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 1
- 102000017910 Adrenergic receptor Human genes 0.000 claims 1
- 101000783605 Homo sapiens 5-hydroxytryptamine receptor 1F Proteins 0.000 claims 1
- 101000689696 Homo sapiens Alpha-1D adrenergic receptor Proteins 0.000 claims 1
- 101100388144 Xenopus laevis drd5 gene Proteins 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 description 175
- 125000001309 chloro group Chemical group Cl* 0.000 description 175
- 239000000460 chlorine Substances 0.000 description 42
- 101100495913 Arabidopsis thaliana CHR17 gene Proteins 0.000 description 34
- 241000700159 Rattus Species 0.000 description 26
- 238000007912 intraperitoneal administration Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 241000894007 species Species 0.000 description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 14
- 239000013626 chemical specie Substances 0.000 description 14
- 125000001624 naphthyl group Chemical group 0.000 description 14
- 239000001301 oxygen Substances 0.000 description 14
- 239000011593 sulfur Substances 0.000 description 14
- 125000000335 thiazolyl group Chemical group 0.000 description 14
- 238000012048 forced swim test Methods 0.000 description 13
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 12
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 12
- 230000003997 social interaction Effects 0.000 description 12
- 239000000935 antidepressant agent Substances 0.000 description 10
- 230000037120 immobility Effects 0.000 description 9
- 208000020401 Depressive disease Diseases 0.000 description 8
- 229940005513 antidepressants Drugs 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 150000001204 N-oxides Chemical class 0.000 description 7
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 7
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 7
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 7
- 125000005605 benzo group Chemical group 0.000 description 7
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 7
- 125000002541 furyl group Chemical group 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000002883 imidazolyl group Chemical group 0.000 description 7
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 7
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 7
- 125000001041 indolyl group Chemical group 0.000 description 7
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 7
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 7
- 125000001786 isothiazolyl group Chemical group 0.000 description 7
- 125000001715 oxadiazolyl group Chemical group 0.000 description 7
- 125000002971 oxazolyl group Chemical group 0.000 description 7
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 7
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 7
- 125000003373 pyrazinyl group Chemical group 0.000 description 7
- 125000003226 pyrazolyl group Chemical group 0.000 description 7
- 125000002098 pyridazinyl group Chemical group 0.000 description 7
- 125000004076 pyridyl group Chemical group 0.000 description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 description 7
- 125000000168 pyrrolyl group Chemical group 0.000 description 7
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 7
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 7
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 7
- 125000001113 thiadiazolyl group Chemical group 0.000 description 7
- 125000001544 thienyl group Chemical group 0.000 description 7
- 125000004306 triazinyl group Chemical group 0.000 description 7
- 125000001425 triazolyl group Chemical group 0.000 description 7
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 5
- 230000009194 climbing Effects 0.000 description 5
- 229960002464 fluoxetine Drugs 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 description 4
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 4
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical compound C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 4
- 208000029364 generalized anxiety disease Diseases 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- 208000019906 panic disease Diseases 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
- JRICMQCTFYLWOU-UHFFFAOYSA-N N1C(=CC2=CC=CC=C12)N.C1(O)=C(O)C(=CC=C1)N Chemical compound N1C(=CC2=CC=CC=C12)N.C1(O)=C(O)C(=CC=C1)N JRICMQCTFYLWOU-UHFFFAOYSA-N 0.000 description 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 3
- 101000608761 Rattus norvegicus Galectin-3 Proteins 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000003943 catecholamines Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 3
- 229960004782 chlordiazepoxide Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229960002296 paroxetine Drugs 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 102220101620 rs759365577 Human genes 0.000 description 3
- 102220059023 rs786201869 Human genes 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical class C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 2
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 2
- 206010021703 Indifference Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010029897 Obsessive thoughts Diseases 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 2
- 230000000338 anxiogenic effect Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000009189 diving Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 102000052301 human GNAZ Human genes 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 125000005545 phthalimidyl group Chemical group 0.000 description 2
- 229940001470 psychoactive drug Drugs 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 210000002348 5-ht neuron Anatomy 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 206010002652 Anorgasmia Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 102000019432 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 241001282135 Poromitra oscitans Species 0.000 description 1
- 101100335469 Rattus norvegicus Fst gene Proteins 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 206010043169 Tearfulness Diseases 0.000 description 1
- 206010048232 Yawning Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000008309 brain mechanism Effects 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002493 climbing effect Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical class N1N=C(C=CC=C1)* 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000005624 indolones Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77534101A | 2001-01-31 | 2001-01-31 | |
PCT/US2002/004608 WO2002060392A2 (fr) | 2001-01-31 | 2002-01-31 | Utilisation d'antagonistes du recepteur gal3 dans le traitement de la depression et/ou de l'anxiete et composes utiles dans de telles methodes |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20030608A2 true HRP20030608A2 (en) | 2005-06-30 |
Family
ID=25104097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030608A HRP20030608A2 (en) | 2001-01-31 | 2003-07-28 | Use of gal3 receptor antagonists for the treatment |
Country Status (22)
Country | Link |
---|---|
EP (3) | EP1363638A4 (fr) |
JP (3) | JP4739650B2 (fr) |
KR (1) | KR20040041092A (fr) |
CN (2) | CN100446767C (fr) |
AU (2) | AU2002247149B2 (fr) |
BG (1) | BG108114A (fr) |
BR (1) | BR0206844A (fr) |
CA (3) | CA2671776C (fr) |
CZ (1) | CZ20032341A3 (fr) |
EA (1) | EA006486B1 (fr) |
HR (1) | HRP20030608A2 (fr) |
HU (1) | HUP0401858A3 (fr) |
IL (2) | IL157102A0 (fr) |
IS (1) | IS6880A (fr) |
MX (1) | MXPA03006812A (fr) |
NO (1) | NO20033388L (fr) |
NZ (1) | NZ527163A (fr) |
PL (1) | PL369270A1 (fr) |
SK (1) | SK9562003A3 (fr) |
UA (1) | UA74421C2 (fr) |
YU (1) | YU60803A (fr) |
ZA (1) | ZA200305686B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100446767C (zh) * | 2001-01-31 | 2008-12-31 | H.隆德贝克有限公司 | Gal3受体拮抗剂在制备治疗抑郁和/或焦虑药物中的应用及在这种方法中有用的化合物 |
AU2003203148A1 (en) * | 2002-02-05 | 2003-09-02 | High Point Pharmaceuticals, Llc | Novel aryl- and heteroarylpiperazines |
CN101973925B (zh) * | 2010-10-15 | 2012-03-28 | 中国药科大学 | 具有抗炎活性的2-吲哚酮类化合物、其制备方法及医药用途 |
WO2015054317A1 (fr) * | 2013-10-07 | 2015-04-16 | Kadmon Corporation, Llc | Inhibiteurs de la rho kinase |
BR112019013571A2 (pt) * | 2016-12-29 | 2020-01-07 | Minoryx Therapeutics S.L. | Compostos heteroarila e seu uso |
WO2020160156A2 (fr) * | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anticorps anti-gal3 et leurs utilisations |
CN113317221B (zh) * | 2021-06-18 | 2023-01-31 | 青岛百宜电器有限公司 | 自动梳毛机 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS50140441A (fr) * | 1974-04-23 | 1975-11-11 | ||
GB1477349A (en) * | 1975-09-24 | 1977-06-22 | Ciba Geigy Ag | Azo pigments |
MA18829A1 (fr) * | 1979-05-18 | 1980-12-31 | Ciba Geigy Ag | Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique |
US4946956A (en) * | 1988-09-21 | 1990-08-07 | Uniroyal Chemical Company, Inc. | Arylenediamine substituted pyrimidines |
JPH02300264A (ja) * | 1989-05-16 | 1990-12-12 | Fuji Photo Film Co Ltd | アミノピリミジンアゾメチン色素とその製造方法 |
JPH02308248A (ja) * | 1989-05-24 | 1990-12-21 | Fuji Photo Film Co Ltd | アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料 |
HUT64323A (en) * | 1992-06-09 | 1993-12-28 | Richter Gedeon Vegyeszet | Process for production new piperazinyl-bis(alkyl-amino)-pyrimidine derivatives |
DK69693D0 (da) * | 1993-06-14 | 1993-06-14 | Neurosearch As | Farven lilla |
CN1104418C (zh) * | 1994-06-15 | 2003-04-02 | 大塚制药株式会社 | 苯并杂环衍生物 |
DE4435477A1 (de) * | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
DK0765858T3 (da) * | 1995-04-12 | 2000-05-01 | Ueno Seiyaku Oyo Kenkyujo Kk | Naphtholderivater og fremgangsmåder til fremstilling af samme |
CZ378497A3 (cs) * | 1995-06-02 | 1998-04-15 | Synthelabo | Deriváty oxazolidinonu, způsob jejich přípravy a jejich terapeutické použití |
WO1998055457A1 (fr) * | 1995-10-13 | 1998-12-10 | Transitions Optical, Inc. | Naphtopyrans substitues |
FR2741072B1 (fr) * | 1995-11-09 | 1997-12-12 | Synthelabo | Derives d'oxazolidin-2-one, leur preparation et leur application en therapeutique |
US6329197B2 (en) | 1996-10-09 | 2001-12-11 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR3 receptors and uses thereof |
DE69804273T2 (de) * | 1997-07-18 | 2002-10-31 | Hoffmann La Roche | 5h-Thiazolo[3,2-a]pyrimidinderivate |
JPH11158073A (ja) * | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
CN1240210A (zh) * | 1998-04-17 | 2000-01-05 | 伊莱利利公司 | 取代的三环化合物 |
CA2334186A1 (fr) * | 1998-06-05 | 1999-12-09 | Regent Court Technologies | Inhibiteurs de monoamine oxydase (mao) et leurs utilisations |
PE20001236A1 (es) * | 1998-11-13 | 2000-11-10 | Lilly Co Eli | Moduladores del receptor de aminoacidos excitadores |
NZ515894A (en) * | 1999-06-02 | 2003-09-26 | Nps Pharma Inc | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
WO2000076980A1 (fr) * | 1999-06-10 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives heterocycliques azotes ou leurs sels |
CA2394727A1 (fr) * | 1999-12-28 | 2001-07-05 | Pharmacopeia, Inc. | Composes de pyrimidine et de triazine presentant une activite inhibant la kinase |
CN100446767C (zh) * | 2001-01-31 | 2008-12-31 | H.隆德贝克有限公司 | Gal3受体拮抗剂在制备治疗抑郁和/或焦虑药物中的应用及在这种方法中有用的化合物 |
-
2002
- 2002-01-31 CN CNB028077547A patent/CN100446767C/zh not_active Expired - Fee Related
- 2002-01-31 KR KR10-2003-7010147A patent/KR20040041092A/ko not_active Application Discontinuation
- 2002-01-31 CA CA2671776A patent/CA2671776C/fr not_active Expired - Fee Related
- 2002-01-31 UA UA2003088106A patent/UA74421C2/uk unknown
- 2002-01-31 SK SK956-2003A patent/SK9562003A3/sk unknown
- 2002-01-31 NZ NZ527163A patent/NZ527163A/en unknown
- 2002-01-31 CZ CZ20032341A patent/CZ20032341A3/cs unknown
- 2002-01-31 EP EP02714918A patent/EP1363638A4/fr not_active Withdrawn
- 2002-01-31 HU HU0401858A patent/HUP0401858A3/hu unknown
- 2002-01-31 CA CA002672805A patent/CA2672805A1/fr not_active Abandoned
- 2002-01-31 YU YU60803A patent/YU60803A/sh unknown
- 2002-01-31 AU AU2002247149A patent/AU2002247149B2/en not_active Ceased
- 2002-01-31 CA CA2438582A patent/CA2438582C/fr not_active Expired - Fee Related
- 2002-01-31 JP JP2002560588A patent/JP4739650B2/ja not_active Expired - Fee Related
- 2002-01-31 EP EP09010003A patent/EP2140864A3/fr not_active Withdrawn
- 2002-01-31 EA EA200300850A patent/EA006486B1/ru not_active IP Right Cessation
- 2002-01-31 PL PL02369270A patent/PL369270A1/xx not_active Application Discontinuation
- 2002-01-31 MX MXPA03006812A patent/MXPA03006812A/es active IP Right Grant
- 2002-01-31 BR BR0206844-3A patent/BR0206844A/pt not_active IP Right Cessation
- 2002-01-31 CN CN200810170443XA patent/CN101406469B/zh not_active Expired - Fee Related
- 2002-01-31 EP EP09010004A patent/EP2140862A3/fr not_active Withdrawn
- 2002-01-31 IL IL15710202A patent/IL157102A0/xx unknown
-
2003
- 2003-07-21 IS IS6880A patent/IS6880A/is unknown
- 2003-07-23 ZA ZA200305686A patent/ZA200305686B/en unknown
- 2003-07-28 HR HR20030608A patent/HRP20030608A2/hr not_active Application Discontinuation
- 2003-07-29 NO NO20033388A patent/NO20033388L/no unknown
- 2003-08-20 BG BG108114A patent/BG108114A/bg unknown
-
2008
- 2008-01-25 AU AU2008200385A patent/AU2008200385B2/en not_active Ceased
-
2009
- 2009-02-19 JP JP2009037247A patent/JP2009173657A/ja active Pending
- 2009-05-14 IL IL198759A patent/IL198759A/en not_active IP Right Cessation
- 2009-07-24 JP JP2009172594A patent/JP2010006813A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7465750B2 (en) | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | |
US20030078271A1 (en) | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
EP1871374B1 (fr) | 2,3 pyrazine sulfonamides substitués comme inhibiteurs de crht2 | |
US8198313B2 (en) | Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
AU2008200385B2 (en) | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
KR100840816B1 (ko) | TNF-α시그널링의 조절물질 | |
US7220775B2 (en) | Compound useful for the treatment of neuropathic pain | |
AU2002247149A1 (en) | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
US20040110821A1 (en) | GAL3 receptor antagonists for the treatment of affective disorders | |
WO2004014307A2 (fr) | Antagonistes de gal3 destines au traitement de douleurs neuropathiques | |
WO2004014376A1 (fr) | Antagonistes du recepteur gal3 pour le traitement des troubles affectifs | |
US6936607B2 (en) | 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety | |
AU2008200380A1 (en) | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
TW200412968A (en) | 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
PPPP | Transfer of rights |
Owner name: H. LUNDBECK A/S, DK |
|
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20090129 Year of fee payment: 8 |
|
ODBI | Application refused |